Clinical trials: in Germany
Aortic Valve Stenosis
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
Transcatheter aortic valve implantation (TAVI) is a key-hole technique to replace an aortic heart valve that is narrowed and/or leaking.
- Trial name
- REVALVE (NCT06557798)
- Testing
- Any commercially available Edwards or Medtronic transcatheter aortic valve with the TAV-in-TAV (Redo TAVI) indication, Surgical explantation and aortic valve replacement, Conservative management
- Where
- 63 sites in Denmark, Finland and 9 more
- Volunteers
- 550 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Pneumococcal Disease
A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and…
- Trial name
- NCT07573462
- Testing
- PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
- Where
- 78 sites in United States, Argentina and 8 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal…
- Trial name
- NCT04973605
- Testing
- Sonrotoclax, Dexamethasone, Carfilzomib
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 246 people
- Sponsor
- BeOne Medicines
Non-small Cell Lung Cancer
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat…
- Trial name
- NCT06345729
- Testing
- Calderasib, Pembrolizumab
- Where
- 246 sites in United States, Argentina and 28 more
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC
Microscopic Colitis
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
This is a parallel, placebo-controlled, multicenter, randomized, double-blind, Phase 2, proof of concept study. The study aims to evaluate the efficacy and safety of SAR444336 in adult participants with microscopic colitis.
- Trial name
- NCT07156175
- Testing
- SAR444336
- Where
- 24 sites in Belgium, Denmark and 7 more
- Volunteers
- 54 people
- Sponsor
- Sanofi
B-Cell Acute Lymphoblastic Leukaemia
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as…
- Trial name
- NCT07476729
- Testing
- Inotuzumab ozogamicin (INO), Blinatumomab
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 750 people
- Sponsor
- Charite University, Berlin, Germany
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-D (NCT05303532)
- Testing
- Durvalumab
- Where
- 123 sites in United States, Argentina and 29 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Breast Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or…
- Trial name
- MoonROSE (NCT07100106)
- Testing
- GDC-4198, Giredestrant, Abemaciclib
- Where
- 77 sites in United States, Australia and 8 more
- Volunteers
- 285 people
- Sponsor
- Genentech, Inc.
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 183 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Paroxysmal Nocturnal Hemoglobinuria
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
- Trial name
- COMMODORE 1 (NCT04432584)
- Testing
- Crovalimab, Eculizumab
- Where
- 80 sites in United States, Belgium and 22 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple…
- Trial name
- NCT06846281
- Testing
- Remibrutinib oral treatment, Ocrelizumab
- Where
- 131 sites in United States, Argentina and 17 more
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers, Safety
Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.
The goal of this clinical trial is to evaluate the safety and tolerability of RCS-21 in healthy volunteers. Participants will be asked to inhale a single dose or multiple doses of RCS-21 and their health status will be constantly…
- Conditions
- Healthy Volunteers, Safety, Tolerability, Pharmacokinetics
- Trial name
- AMIR-21 (NCT06752122)
- Testing
- RCS-21 (SAD), RCS-21 (MD)
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- RNATICS GmbH
Alpha 1 Antitrypsin Deficiency
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standard doses of the same medicine given through a vein.
- Trial name
- SWIFT-SC (NCT07555483)
- Testing
- Alpha-1 15%, Liquid Alpha1-PI
- Where
- 22 sites in United States, Denmark and 7 more
- Volunteers
- 40 people
- Sponsor
- Grifols Therapeutics LLC
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Breast Cancer
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
This study will evaluate the safety and efficacy of inavolisib combination therapies in participants with untreated, PIK3CA-mutated, Stage II-III, estrogen receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2…
- Trial name
- NCT07054190
- Testing
- Inavolisib, Ribociclib, Letrozole
- Where
- 37 sites in United States, Argentina and 5 more
- Volunteers
- 120 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer Metastatic
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
AIO-TRK/YMO-0425 (High Five) is a phase III, open-label randomized-controlled, multicenter study to evaluate the progression-free survival by the addition of platinum-based chemotherapy to immunotherapy (IO) compared to IO…
- Trial name
- High Five (NCT07715396)
- Testing
- Tislelizumab, Tislelizumab Combined With Chemotherapy, Pembrolizumab
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- AIO-Studien-gGmbH
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Sickle Cell Disease
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
This clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to…
- Trial name
- NCT05031780
- Testing
- Mitapivat
- Where
- 91 sites in United States, Belgium and 14 more
- Volunteers
- 286 people
- Sponsor
- Agios Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.